AIXN vs CVS
AiXin Life International, Inc. and CVS Health Corp., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AIXN | CVS |
|---|---|---|
| Revenue | $1.5M | $402.1B |
| Net income | $-2.0M | $1.8B |
| Gross margin | 41.7% | 45.0% |
| Net margin | −137.1% | 0.4% |
| Return on equity | · | 2.3% |
| Diluted EPS | −$0.08 | $1.39 |
| Dividend / share | · | $2.66 |
| Payout ratio | · | 192.1% |
| Free cash flow | $-2.0M | $7.8B |
| Equity | $-6.6M | $75.2B |
| Net debt / equity | · | 0.69× |
| Current ratio | 0.12× | 0.84× |
| Revenue CAGR 5y | −9.5% | 8.4% |
| Profit CAGR 5y | · | −24.4% |
CVS bills 269947.4× the revenue of AIXN, and AIXN closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AIXN | CVS |
|---|---|---|
| FY2025 | $1.5M | $402.1B |
| FY2024 | $3.8M | $372.8B |
| FY2023 | $4.1M | $357.8B |
| FY2022 | $2.7M | $322.5B |
| FY2021 | $3.1M | $292.1B |
| FY2020 | $2.5M | $268.7B |
| FY2019 | $3.4M | $256.8B |
| FY2018 | $414,281 | $194.6B |
| FY2017 | $688,095 | $184.8B |
| FY2016 | $3.1M | $177.5B |
Bottom line
| Fiscal year | AIXN | CVS |
|---|---|---|
| FY2025 | $-2.0M | $1.8B |
| FY2024 | $-2.8M | $4.6B |
| FY2023 | $-2.1M | $8.3B |
| FY2022 | $-6.4M | $4.3B |
| FY2021 | $-267,236 | $8.0B |
| FY2020 | $1.0M | $7.2B |
| FY2019 | $1.9M | $6.6B |
| FY2018 | $-1.3M | $-594.0M |
| FY2017 | $-4.3M | $6.6B |
| FY2016 | $-2.1M | $5.3B |
13 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$402,065,510,573 | CVS |
| FY2024 | −$372,805,175,699 | CVS |
| FY2023 | −$357,771,910,201 | CVS |
| FY2022 | −$322,464,291,440 | CVS |
| FY2021 | −$292,107,933,767 | CVS |
| FY2020 | −$268,703,548,945 | CVS |
| FY2019 | −$256,772,581,792 | CVS |
| FY2018 | −$194,578,585,719 | CVS |
| FY2017 | −$184,785,311,905 | CVS |
| FY2016 | −$177,542,917,275 | CVS |
| FY2014 | −$139,367,000,000 | CVS |
| FY2013 | −$126,761,000,000 | CVS |
| FY2012 | −$123,120,000,000 | CVS |
CVS has reported the higher revenue in every one of these 13 fiscal years. The gap has widened since the earliest year compared.
13 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −137.6 pp | CVS |
| FY2024 | −73.6 pp | CVS |
| FY2023 | −53.5 pp | CVS |
| FY2022 | −236.5 pp | CVS |
| FY2021 | −11.5 pp | CVS |
| FY2020 | +38.8 pp | AIXN |
| FY2019 | +52.8 pp | AIXN |
| FY2018 | −325.5 pp | CVS |
| FY2017 | −622.0 pp | CVS |
| FY2016 | −70.5 pp | CVS |
The higher net margin has changed hands between AIXN and CVS over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
AIXN's net margin has been more volatile than CVS's over the 10 comparable fiscal years — 194.6 percentage points of standard deviation against 1.2.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AIXN and CVS over these 10 fiscal years — AIXN led in 2 and CVS in 8.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
AIXN's return on equity has been more volatile than CVS's over the 3 comparable fiscal years — 64.6 percentage points of standard deviation against 0.8.
3 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AIXN and CVS over these 3 fiscal years — AIXN led in 1 and CVS in 2.
3 of 19 comparable fiscal years — a year missing data on either side is not counted.